Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction.

  title={Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction.},
  author={Rafael Diaz and Abhinav Goyal and Shamir R. Mehta and Rizwan Afzal and Denis Xavier and P H N Pais and Susan Chrolavicius and Jun Zhu and Khawar Abbas Kazmi and Lisheng Liu and Andrzej J Budaj and Mohammad Zubaid and Alvaro A Avezum and Mikhail Ya. Ruda and Salim Yusuf},
  volume={298 20},
CONTEXT The clinical benefit of glucose-insulin-potassium (GIK) infusion in patients with ST-segment elevation myocardial infarction (STEMI) is unclear. While some smaller trials suggest benefit, in the CREATE-ECLA trial, GIK infusion had no effect on 30-day mortality in 20,201 patients. OBJECTIVES To determine the association between GIK infusion therapy and 30-day and 6-month outcomes in patients with STEMI. DESIGN, SETTING, AND PARTICIPANTS Primary analysis of the OASIS-6 GIK randomized… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 74 extracted citations


Publications referenced by this paper.
Showing 1-10 of 12 references

Clinical experience with glucose-insulin-potassium therapy in acute myocardial infarction

  • CE Rackley, RO JrRussell, WJ Rogers, JA Mantle, HG McDaniel, SE. Papapietro
  • Am Heart J. 1981;102(6
  • 1981
Highly Influential
10 Excerpts

Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care Trial

  • http://www.clinicaltrials .gov/ct/show…
  • 2007

Similar Papers

Loading similar papers…